secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2026-04-20T23:59:59+00:00
Accession:  0001193125-26-163909
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Damora Therapeutics dismisses EY Denmark auditor, appoints EY US
----------------------------------------------------------------

- Audit Committee dismissed EY Denmark on April 17, 2026; EY US appointed same day.
- No disagreements or reportable events occurred in FY 2024 or 2025 or the subsequent interim period.
- EY Denmark's 2024 report included a going-concern explanatory paragraph.
- Company provided EY Denmark with disclosures; EY Denmark's letter to SEC filed as Exhibit 16.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000119312526163909/0001193125-26-163909-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000119312526163909/dmra-20260417.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-163909

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer